Go Pro
NASDAQ:REVB

Revelation Biosciences (REVB) Stock Price, News & Analysis

Revelation Biosciences logo
$1.15 +0.10 (+9.63%)
As of 04:00 PM Eastern

About Revelation Biosciences Stock (NASDAQ:REVB)

Advanced

Key Stats

Today's Range
$1.05
$1.15
50-Day Range
$0.95
$1.18
52-Week Range
$0.88
$11.72
Volume
61,453 shs
Average Volume
292,181 shs
Market Capitalization
$4.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

REVB MarketRank™: 

Revelation Biosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revelation Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Revelation Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Revelation Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Revelation Biosciences are expected to grow in the coming year, from ($5.18) to ($2.89) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revelation Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revelation Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Revelation Biosciences has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Revelation Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.56% of the float of Revelation Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Revelation Biosciences has a short interest ratio ("days to cover") of 0.51, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Revelation Biosciences has recently increased by 2.62%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Revelation Biosciences does not currently pay a dividend.

  • Dividend Growth

    Revelation Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Revelation Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Revelation Biosciences this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for REVB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Revelation Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.80% of the stock of Revelation Biosciences is held by insiders.

  • Percentage Held by Institutions

    12.80% of the stock of Revelation Biosciences is held by institutions.

  • Read more about Revelation Biosciences' insider trading history.
Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REVB Stock News Headlines

Equities Analysts Set Expectations for REVB Q3 Earnings
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
REVB Poised for Big Year
REVB Comes to Agreement with FDA
See More Headlines

REVB Stock Analysis - Frequently Asked Questions

Revelation Biosciences' stock was trading at $3.1992 on January 1st, 2026. Since then, REVB shares have decreased by 65.0% and is now trading at $1.12.

Revelation Biosciences, Inc. (NASDAQ:REVB) issued its quarterly earnings data on Friday, August, 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.01.

Revelation Biosciences's stock reverse split on Tuesday, January 28th 2025.The 1-16 reverse split was announced on Friday, January 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Wayfair (W), Abbott Laboratories (ABT), JPMorgan Chase & Co. (JPM) and Bank of America (BAC).

Company Calendar

Last Earnings
8/07/2026
Today
8/17/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:REVB
CIK
1810560
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($12.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-100.19%
Return on Assets
-82.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.22
Quick Ratio
6.22

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.28 per share
Price / Book
0.90

Miscellaneous

Outstanding Shares
3,980,000
Free Float
3,792,000
Market Cap
$4.58 million
Optionable
Not Optionable
Beta
-0.15
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:REVB) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners